A5102790925- HIV/AIDS drug development and treatment
- HIV Research and Treatment
- HIV/AIDS Research and Interventions
- HIV-related health complications and treatments
- Osteoarthritis Treatment and Mechanisms
- COVID-19 Clinical Research Studies
- Lower Extremity Biomechanics and Pathologies
- Phytochemicals and Antioxidant Activities
- Smoking Behavior and Cessation
- Total Knee Arthroplasty Outcomes
- Cancer Risks and Factors
- Hepatitis C virus research
- Nutritional Studies and Diet
- Radiomics and Machine Learning in Medical Imaging
- Long-Term Effects of COVID-19
- SARS-CoV-2 and COVID-19 Research
- Hepatitis B Virus Studies
- Phytochemistry and Biological Activities
- Essential Oils and Antimicrobial Activity
- Viral-associated cancers and disorders
- Pharmacological Effects and Toxicity Studies
- Drug-Induced Adverse Reactions
- Biological Activity of Diterpenoids and Biflavonoids
- Global Cancer Incidence and Screening
- Knee injuries and reconstruction techniques
Wuhan University
2019-2025
State Key Laboratory of Hybrid Rice
2025
Twelfth Guangzhou City People's Hospital
2025
Gannan Medical University
2024
Third Affiliated Hospital of Southern Medical University
2022-2024
Wenzhou Medical University
2024
Huazhong University of Science and Technology
2023
Second People’s Hospital of Yibin
2021-2023
Gilead Sciences (United States)
2010-2020
Bay Medical Center
2020
Remdesivir, a nucleotide analogue prodrug that inhibits viral RNA polymerases, has shown in vitro activity against SARS-CoV-2. We provided remdesivir on compassionate-use basis to patients hospitalized with Covid-19, the illness caused by infection Patients were those confirmed SARS-CoV-2 who had an oxygen saturation of 94% or less while they breathing ambient air receiving support. received 10-day course remdesivir, consisting 200 mg administered intravenously day 1, followed 100 daily for...
Initiation of antiretroviral therapy (ART) often leads to weight gain. While some this gain may be an appropriate return-to-health effect, excessive increases in lead obesity. We sought explore factors associated with several randomized comparative clinical trials ART initiation.We performed a pooled analysis 8 controlled treatment-naive people living human immunodeficiency virus (HIV) initiating between 2003 and 2015, comprising >5000 participants 10 000 person-years follow-up. used...
Objective: To evaluate the antiviral activity, safety, pharmacokinetics, and pharmacokinetics/pharmacodynamics of short-term monotherapy with tenofovir alafenamide (TAF), a next-generation (TFV) prodrug. Design: A phase 1b, randomized, partially blinded, active- placebo-controlled, dose-ranging study. Methods: Treatment-naive experienced HIV-1–positive adults currently off antiretroviral therapy were randomized to receive 8, 25, or 40 mg TAF, 300 disoproxil fumarate (TDF), placebo, each once...
In 2 double-blinded Phase 3 trials, 1733 antiretroviral-naive participants were randomized to tenofovir alafenamide (TAF), a prodrug versus disoproxil fumarate (TDF), each coformulated with elvitegravir/cobicistat/emtricitabine (E/C/F). At 96 weeks, 86.6% in the TAF arm and 85.2% TDF had HIV-1 RNA <50 c/mL [difference 1.5%; (95% CI: -1.8% 4.8%)]. With TAF, there are smaller declines bone mineral density more favorable changes proteinuria, albuminuria, tubular no cases of proximal tubulopathy...
We compared the efficacy of antiviral agent, remdesivir, versus standard-of-care treatment in adults with severe coronavirus disease 2019 (COVID-19) using data from a phase 3 remdesivir trial and retrospective cohort patients COVID-19 treated standard care.
GS-9137 is a potent low-nanomolar strand transfer inhibitor of HIV-1 integrase.The antiviral activity, tolerability, pharmacokinetics, and pharmacodynamics were evaluated in randomized, double-blind, placebo-controlled monotherapy study 40 HIV-1- infected patients not receiving antiretroviral therapy with an RNA between 10,000 300,000 copies/mL CD4 count 200 cells/microL or greater. matching placebo was administered food for 10 days at 5 dosage regimens (200, 400, 800 mg BID, QD, 50 mg+100...
Background. Coinfection with human immunodeficiency virus type 1 (HIV-1) increases the risk of hepatitis B (HBV)-associated progressive liver disease. Lamivudine has potent activity against both HIV-1 and HBV; however, lamivudine-resistance mutations in HBV frequently develop. Methods. Substudies safety efficacy tenofovir disoproxil fumarate (tenofovir DF) for patients coinfected HIV were undertaken within 2 phase 3 randomized controlled trials involving antiretroviral therapy-experienced...
Results from 2 placebo-controlled intensification trials of tenofovir disoproxil fumarate (DF) in treatmentexperienced human immunodeficiency type 1 (HIV-1)-infected patients (n = 332) were integrated to determine the effects resistance at baseline on HIV-1 RNA response. In these trials, there was a high prevalence mutations, with 94% having nucleoside-associated mutations and 71% thymidine analogue-associated (TAMs). Statistically significant reductions associated DF treatment, relative...
Background: Study 903 is a phase 3 trial with completed 144-week, double-blind comparing tenofovir DF (TDF) to stavudine (d4T) in combination lamivudine (3TC) and efavirenz (EFV) an ongoing additional 336-week open-label extension phase. Method: Patients Brazil, Argentina, the Dominican Republic who 144-week on TDF were eligible roll over (weeks 144-480). Results from interim week 288 analysis are presented. Results: Eighty-six patients (62% male, 70% white) initially randomized arm...
Compared with tenofovir disoproxil fumarate (TDF), alafenamide (TAF) has been associated improvement in markers of renal dysfunction individual randomized trials; however, the comparative incidence clinically significant events remains unclear.We used a pooled data approach to increase person-years drug exposure analysed, maximizing our ability detect differences outcomes.We clinical safety across 26 treatment-naive and antiretroviral switch studies compare proximal tubulopathy...
Tenofovir alafenamide (formerly GS-7340) is a new oral prodrug of tenofovir, nucleotide analogue that inhibits HIV-1 reverse transcription. Unlike the currently marketed tenofovir prodrug, disoproxil fumarate, stable in plasma and then rapidly converted into once inside cells. The pharmacokinetics, safety antiviral activity 40 or 120 mg compared with 300 fumarate when administered as monotherapy daily for 14 days HIV-1-infected, treatment-naive subjects was studied. Administration resulted...
Methods. An international, randomized, double-blind, double-dummy, active-controlled trial was conducted to evaluate the efficacy and safety of COBI versus ritonavir (RTV) as a pharmacoenhancer atazanavir (ATV) in combination with emtricitabine (FTC)/tenofovir disoproxil fumarate (TDF) treatment-naive patients. The primary end point human immunodeficiency virus type 1 (HIV-1) RNA load <50 copies/mL at week 48 by Food Drug Administration snapshot algorithm; noninferiority margin 12%.
Background: Development of safe and effective SARS-CoV-2 therapeutics is a high priority. Amubarvimab romlusevimab are noncompeting anti–SARS-CoV-2 monoclonal antibodies with an extended half-life. Objective: To assess the safety efficacy amubarvimab plus romlusevimab. Design: Randomized, placebo-controlled, phase 2 3 platform trial. (ClinicalTrials.gov: NCT04518410) Setting: Nonhospitalized patients COVID-19 in United States, Brazil, South Africa, Mexico, Argentina, Philippines. Patients:...
Associations between indoor air pollution from Chinese-style cooking and lung cancer have been found in several investigations. To provide more detailed estimates of the associations while accounting for key confounding factors, we conducted a population-based, case-control study among nonsmoking women living Shanghai, People's Republic China. Five hundred four incident, primary cases diagnosed February 1992 through January 1994 were identified population-based Shanghai Cancer Registry. A...
Background. This phase 2, randomized, active-controlled, 48-week study assessed the noninferiority of human immunodeficiency virus (HIV) integrase inhibitor elvitegravir to comparator ritonavir-boosted protease (CPI/r) in treatment-experienced subjects. Methods. Subjects had HIV RNA levels ⩾1000 copies/mL and ⩾1 resistance mutation. received nucleoside or nucleotide reverse-transcriptase inhibitors (NRTIs) with without T-20 either CPI/r once-daily at a dose 20 mg, 50 125 mg (blinded dose)...
Study GS-01-934 was a randomized open-label phase III study comparing efavirenz and tenofovir/emtricitabine to zidovudine/lamivudine in treatment-naive HIV-1-infected individuals. Through 144 weeks, 50 of 487 participants without baseline nonnucleoside reverse transcriptase inhibitor resistance by population sequencing (efavirenz/tenofovir/emtricitabine, n = 19; efavirenz/zidovudine/lamivudine, 31) experienced virologic failure (>400 copies/ml). Here, we analyzed whether the presence low...
Epidemiologic evidence regarding the association between consumption of green tea and lung cancer is limited inconclusive, although experimental studies have shown consistently that preparations polyphenols may inhibit induction a variety cancers, including cancer. In this population-based case-control study, we examined past risk We identified 649 incident cases primary among women diagnosed from February 1992 through January 1994 using Shanghai Cancer Registry. randomly selected control...
Background: HIV-infected, treatment-experienced adults with a history of prior resistance and regimen failure can be virologically suppressed but may require multitablet regimens associated lower adherence potential development. Methods: We enrolled 2-class to 3-class drug at least 2 failures into this phase 3, open-label, randomized study. The primary endpoint was the percentage participants HIV-1 RNA <50 copies per milliliter week 24 [Food Drug Administration (FDA) snapshot algorithm]....
Background: No investigations have thoroughly explored the feasibility of combining magnetic resonance (MR) images and deep-learning methods for predicting progression knee osteoarthritis (KOA). We thus aimed to develop a potential model OA based on MR clinical setting. Methods: A longitudinal case-control study was performed using data from Foundation National Institutes Health (FNIH), composed progressive cases [182 (OA) knees with both radiographic pain 24–48 months] matched controls (182...